浏览项目标签 “FSHD Research - FSHD Society”

FSHD University – FSHD Experiences: Insights from Europe

发布日期 7 月 20th, 20237/20/23

1:00 PM ET | noon CT | 11:00 AM MT | 10:00 AM PT Our speaker is Megan McNiff, a research associate from the John Walton Muscular Dystrophy Research Centre, […]

归档：

标签 前列腺增生症研究, 家庭健康与发展大学, 研究

更多信息

HAT Trick to Block the DUX4 Gene

发布日期 10 月 24th, 201910/24/19

Researchers Identify a New Compound that Inhibits the Activity of DUX4 By Alec DeSimone, PhD University of Massachusetts Medical School Led by a team at the University of Minnesota, Minneapolis, […]

归档： 前列腺增生症研究

标签 DUX4, FSHD, 前列腺增生症研究

更多信息

An undeniable sense of optimism

发布日期 11 月 30th, 201711/30/17

In this interview, Dr. Jeffery Statland of the University of Kansas Medical Center explains how FSH Society funding seeded the creation of the seven-site Clinical Trial Research Network (CTRN), which […]

归档： 筹款与活动

标签 FSH 肌肉萎缩症, FSHD, 前列腺增生症研究, 研究, 研究突破

更多信息

Intriguing research on tyrosine kinase inhibition as a potential therapy for FSHD: Sunitinib rescues muscle cells’ ability to develop

发布日期 4 月 19th, 20174/19/17

Written by Jim Albert Eldersburg, Maryland   A cancer drug has been shown to potentially rescue some of the damaging effects of DUX4, the gene implicated in FSH muscular dystrophy. […]

归档： 前列腺增生症研究

标签 前列腺增生症研究, Sunitinib

更多信息

关于 BET 抑制剂在前列腺增生症治疗中的潜在应用的问与答

发布日期 3 月 15, 20173/15/17

On February 13, Canadian biotech, Reserverlogix announced that facioscapulohumeral muscular dystrophy (FSHD) is one of two new indications it is pursuing involving its lead drug, apabetalone (RVX-208) which inhibits bromodomain […]

归档： 前列腺增生症研究

标签 阿帕他酮, BET 抑制剂, Fran Sverdrup, 前列腺增生症研究, Reserverlogix

更多信息